Hexvix (Hexaminolevulinate)

Hexvix is a prescription solution containing 85 mg of hexaminolevulinate per 50 mL for intravesical instillation. It is a photosensitizing diagnostic agent used in the European market to aid detection of non‑muscle invasive bladder cancer during cystoscopy. The product is administered directly into the bladder, where the prodrug selectively accumulates in malignant urothelial cells, enabling fluorescence visualization under blue light. This approach supports real‑time assessment and targeted biopsy.

Hexvix is indicated for visual enhancement of bladder lesions during cystoscopic examination.

- Detection of non‑muscle‑invasive bladder cancer (NMIBC) during standard white‑light cystoscopy. - Identification of carcinoma in situ (CIS) of the bladder. - Guidance of transurethral resection of bladder tumor (TURBT) by highlighting suspicious areas. - Assessment of treatment response or recurrence in patients under surveillance. - Differentiation between inflammatory changes and true malignant lesions. - Facilitation of targeted biopsies to improve diagnostic yield.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of the agent.

Common: - Mild bladder irritation or dysuria, usually resolving within hours. - Transient hematuria that clears without intervention. - Increased urinary urgency or frequency during the observation period. - Mild flank discomfort or pelvic pressure after instillation.

Serious: - Severe allergic reaction, including anaphylaxis or angioedema, requiring immediate medical attention. - Persistent urinary retention that may necessitate catheter placement. - Phototoxic skin reaction if the patient is exposed to intense light sources before the drug is cleared.

Before using Hexvix, clinicians should evaluate several safety considerations to minimize risks associated with the procedure and the photosensitizer.

- Confirm absence of active urinary tract infection prior to instillation. - Ensure the patient has not received porphyrin‑related drugs (e.g., certain antibiotics, antimalarials) within the past two weeks. - Verify that the bladder is adequately drained and that no obstructive lesions are present. - Advise patients to avoid direct sunlight and strong indoor lighting for at least 24 hours after the procedure. - Monitor for signs of allergic reaction during and after administration. - Use caution in patients with known hypersensitivity to aminolevulinic acid derivatives. - Pregnancy status is unknown; avoid use unless benefits outweigh potential risks.

Hexvix may interact with other agents that affect porphyrin metabolism or cause photosensitivity.

Avoid: - Concurrent use of other photosensitizing drugs (e.g., tetracyclines, sulfonamides, amiodarone) that could amplify fluorescence or skin reactions. - Administration of porphyrin‑inducing agents such as phenobarbital or griseofulvin within two weeks before the procedure.

Use with caution: - Systemic chemotherapy or immunotherapy that may alter bladder mucosa integrity; monitor for increased irritation. - Anticoagulant therapy, as minor hematuria may be more pronounced. - Use of intravesical agents (e.g., BCG) shortly before or after Hexvix; schedule appropriately to avoid overlapping effects.